四環醫藥(00460.HK):與Hugel分銷協議不會因收購受到影響
四環醫藥(00460.HK)公佈,注意到近期有媒體就康橋資本對Hugel的收購作出報道,其中有報道稱公司未來對Hugel某些產品於中國的獨家代理權將會受到Hugel收購的影響。公司表示,根據早前公佈,相信與Hugel就A型肉毒毒素「樂提葆」及玻尿酸產品訂立的獨家分銷協議之條款及其項下的權利,不會因Hugel收購而受到影響。
公司進一步注意到,界面新聞於2021年9月27日發佈的關於康橋資本獨家迴應的相關報道,公司旗下醫美業務主體北京?顏空間科技有限公司,於2021年9月10日以侵犯商業祕密爲由起訴康橋資本,該訴訟已被北京知識產權法院正式受理。公司強調,將根據所有適用法律來積極尋求保護其權利。公司自與Hugel簽署獨家分銷協議以來,一直是Hugel在中國的長期戰略合作夥伴,將持續致力於保持和Hugel的長期戰略合作關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.